850607-58-8|Darotropium bromide|(1R,5R)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide|-范德生物科技公司

Darotropium bromide

NMR下载 COA and HPLC MSDS下载
names：
(1R,5R)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide
CAS号：
850607-58-8
MDL Number：
MF(分子式)： C24H29BrN2 MW(分子量)： 425.414
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Darotropium bromide
英文别名	GSK233705B; GSK 233705B; GSK-233705B; GSK233705; GSK 233705; GSK-233705; Darotropium bromide
CAS号	850607-58-8
SMILES	C[N+]1(C)[C@@]2([H])CC(CC(C3=CC=CC=C3)(C#N)C4=CC=CC=C4)C[C@@]1([H])CC2.[Br-]
Inchi	InChI=1S/C24H29N2.BrH/c1-26(2)22-13-14-23(26)16-19(15-22)17-24(18-25,20-9-5-3-6-10-20)21-11-7-4-8-12-21;/h3-12,19,22-23H,13-17H2,1-2H3;1H/q+1;/p-1/t22-,23-;/m1./s1
InchiKey	CWRNUVNMUYSOFQ-OHIDFYLOSA-M
分子式 Formula	C24H29BrN2
分子量 Molecular Weight	425.414
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Darotropium bromide(CAS:850607-58-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Darotropium bromide is discontinued (DEA controlled substance). Darotropium bromide, also known as GSK233705 or GSK233705B, is an inhaled, long-acting muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). GSK233705 demonstrated bronchodilatory activity and were well tolerated. Although the onset of bronchodilation was rapid, it was not sustained over 24 h making it unsuitable for once-daily dosing.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Beier J, van Noord J, Deans A, Brooks J, Maden C, Baggen S, Mehta R, Cahn A.Safety and efficacy of dual therapy with GSK233705 and salmeterol versusmonotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study inpartially reversible COPD patients. Int J Chron Obstruct Pulmon Dis.2012;7:153-64. doi: 10.2147/COPD.S26100. Epub 2012 Mar 5. PubMed PMID: 22419863;PubMed Central PMCID: PMC3299545.

[2]Bateman E, Feldman G, Kilbride S, Brooks J, Mehta R, Harris S, Maden C, CraterG. Efficacy and safety of the long-acting muscarinic antagonist GSK233705delivered once daily in patients with COPD. Clin Respir J. 2012 Oct;6(4):248-57.doi: 10.1111/j.1752-699X.2011.00278.x. Epub 2012 Feb 13. PubMed PMID: 22329914.

[3] Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma.Br J Pharmacol. 2008 Oct;155(3):291-9. doi: 10.1038/bjp.2008.284. Epub 2008 Jul7. Review. PubMed PMID: 18604231; PubMed Central PMCID: PMC2567883.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开